Pharma Marketing News Vol. 10, No. 2: JANUARY 19, 2011
Welcome to Volume 10, Issue #2 (JANUARY 19, 2011) of Pharma Marketing News.
Pharma Marketing News Vol. 10, No. 15: 12 October 2011
Welcome to Volume 10, Issue #15 (12 OCTOBER 2011) of Pharma Marketing News.
The British Pharmaceutical Industry Issues Social Media Guidance for Adverse Event Reporting
Once again the Brits have beaten the US in issuing useful guidelines for social media use by the pharmaceutical industry! As I reported back in April, 2011, the Prescription Medicines Code of Practice Authority (PMCPA), which oversees the self-regulatory code of the Association of the British Pharmaceutical Industry (ABPI), published
Pharma Marketing News Vol. 10, No. 17: 10 November 2011
Welcome to Volume 10, Issue #17 (10 NOVEMBER 2011) of Pharma Marketing News.
Pharma Marketing News Vol. 10, No. 11: 21 June 2011
Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.
The Pharmaguy Social Media Timeline&trade: A Record of Social Media Events Impacting the Pharmaceutical...
The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.
The Pozen Digital Advisory Board
A conversation with Elizabeth A. Cermak, EVP, and Chief Commercial Officerat Pozen, Raj Amin, CEO and Co-Founder of HealthiNation, and Bonin Bough, Senior Global Director of Digital and Social Media, PepsiCo, about the who, what, why behind the Pozen Digital Advisory Board, an esteemed group of digital thought-leaders both in and outside of healthcare.
Will Critics Kill Pharma’s Social Media Golden Egg Laying Goose?
The fear is that if the first steps by pharma to engage in social media conversation are too harshly scrutinized and criticized, the drug industry will shy away from getting more involved in social media.
Limiting Bias in Commercially Supported CME
Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.
Digitally-Feeble Pharma
Is Your Brand a Digital Genius or a Feeble-Minded Idiot? When it comes to digital IQ, some brands are geniuses and some are feeble-minded idiots, according to the 'L2 Digital IQ Index' for pharmaceutical brands, a first-of-its kind measurement of the digital competence of 51 pharma brands across eight therapeutic categories.
